Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
This usually includes: Patients body mass index (BMI) confirms obesity or overweight status Medical history showing previous weight loss attempts through diet, exercise, or other medications Diagnosis of obesity-related conditions, such as OSA Evidence that the patient does not have contraindications like a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) Providing thorough and accurate documentation speeds up the approval process, reducing delays in starting treatment
In adults with type 2 diabetes, the 12 mg dose achieved approximately 16.9% mean body weight reduction at 24 weeks
liraglutide is Victoza and Saxenda
Published clinical research has characterised the compound in controlled trials: a Phase 2 obesity trial reported dose-dependent body-weight change in the study population (Jastreboff et al., 2023), and a separate Phase 2 trial investigated the GIP/GLP-1/glucagon agonist in people with type 2 diabetes (Rosenstock et al., 2023)
US$ 28.47
US$ 20.09
US$ 25.01
US$ 27.07
US$ 23.06
